Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma

Phase 1

Not yet recruiting

• Conditions: Osteosarcoma; Bone Cancer

• Registration Number: NCT06562673
• Lead Sponsor: Shanghai 6th People's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-10
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> 1. Histologically or cytologically confirmed diagnosis of osteosarcoma patients aged<br> 18-40 years old;<br><br> 2. Accept to receive treatment with neoadjuvant chemotherapy regimen and completing the<br> standard treatment course; Voluntary informed consent, joining the study with good<br> compliance.<br><br> 3. Have detailed medical data (such as medical history data, laboratory reports of<br> blood routine and liver and kidney functions, pathology reports, etc.), and complete<br> records of postoperative follow-up.<br><br>Exclusion Criteria:<br><br> 1. Combined history of acute injury, infection and surgery in the last 3 months;<br><br> 2. Those with severe liver and kidney function abnormalities;<br><br> 3. Those who are using anti-inflammatory drugs;<br><br> 4. Pre-existing hematologic diseases before treatment;<br><br> 5. Combined with other malignant tumors;<br><br> 6. Diagnosed with autoimmune disease or using steroid drugs for more than 1 month<br> before treatment;<br><br> 7. Suffering from mental illness or cognitive dysfunction.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of Treatment-Emergent Adverse Events;Incidence of tumor response

Secondary Outcome Measures

Name	Time	Method
Microvessel density